| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | NCR2 |
| Uniprot No | O95944 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 19-130aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMSQAQSKAQVLQSVAGQTLTVRCQYPPTGS LYEKKGWCKEASALVCIRLVTSSKPRTMAWTSRFTIWDDPDAGFFTVTMT DLREEDSGHYWCRIYRPSDNSVSKSVRFYLVVS |
| 预测分子量 | 15 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于NCR2重组蛋白的3篇参考文献示例(文献信息为示例，建议通过学术数据库检索最新研究)：
1. **《Structural analysis of recombinant NCR2 reveals its ligand-binding mechanism》**
- **作者**: Alicia M. Holtzclaw, et al.
- **摘要**: 通过X射线晶体学解析NCR2重组蛋白的三维结构，揭示其与病毒或肿瘤细胞表面配体(如NKp44配体)结合的分子机制，为设计基于NCR2的免疫疗法提供结构基础。
2. **《Recombinant NCR2 enhances antiviral activity of NK cells in vitro》**
- **作者**: Giuseppe R. Potenza, et al.
- **摘要**: 研究显示，外源性添加重组NCR2蛋白可增强自然杀伤(NK)细胞对流感病毒感染的靶细胞的杀伤能力，表明NCR2在抗病毒免疫中的潜在应用价值。
3. **《NCR2 recombinant protein as a biomarker in tumor immunotherapy》**
- **作者**: Elisabetta Traggiai, et al.
- **摘要**: 探讨重组NCR2蛋白在肿瘤微环境中与肿瘤细胞表面蛋白的相互作用，提出其作为评估NK细胞活性及免疫治疗效果的生物标志物的可能性。
**提示**：以上为模拟示例，实际文献请通过PubMed、Web of Science或Google Scholar以“NCR2 recombinant protein”、“NK cell receptor NCR2”等关键词检索近年发表的研究。
**Background of NCR2 Recombinant Protein**
NCR2 (Natural Cytotoxicity Triggering Receptor 2), also known as NKp44. is a key activating receptor predominantly expressed on natural killer (NK) cells, a type of cytotoxic lymphocyte critical in innate immunity. It belongs to the NCR family, which includes NKp30. NKp46. and NKp44 (NCR2), and plays a vital role in recognizing and eliminating infected or malignant cells. NCR2 is structurally characterized by an extracellular immunoglobulin-like domain, a transmembrane region, and a short cytoplasmic tail lacking intrinsic signaling motifs. Instead, it associates with adaptor proteins like DAP12 or FcεRIγ to transmit activation signals, triggering NK cell cytotoxicity and cytokine production.
The gene encoding NCR2 is located on human chromosome 6 and is selectively expressed upon NK cell activation. Its ligands include viral hemagglutinins, heparan sulfate proteoglycans, and tumor-associated markers, though precise molecular interactions remain under investigation. Dysregulation of NCR2 has been implicated in immune evasion by pathogens and cancers, highlighting its therapeutic relevance.
Recombinant NCR2 protein is produced using biotechnological platforms (e.g., bacterial, insect, or mammalian cell systems) to express the receptor’s extracellular domain. This engineered protein retains ligand-binding capability and is widely used in structural studies, ligand screening, and functional assays to decipher NCR2-mediated immune responses. Additionally, it serves as a tool for developing immunotherapies, such as bispecific antibodies or chimeric antigen receptors (CARs), aimed at enhancing NK cell targeting of diseased cells.
Research on NCR2 recombinant protein continues to advance understanding of NK cell biology and its applications in treating infections, cancers, and immune disorders, positioning it as a promising candidate in next-generation immunotherapeutic strategies.
×
